Remove keyword biopharma-industry
article thumbnail

Overview of FDA Expedited Development and Approval Programs for Serious Conditions

Impact Pharmaceutical Services

In May of 2014 and February of 2019 , the FDA released final Guidance for Industry outlining the Agency’s policies and procedures regarding expedited development and review programs for new drugs and biologics intended to treat serious or life-threatening conditions. May 4, 2022 | Nathaniel DiTommaso, MS, Regulatory Affairs Manager.

FDA 52
article thumbnail

What CX Tech Innovations Options Are Ripe for Consideration?

pharmaphorum

The text can then be scanned and analysed for keywords. Built with Microsoft clouds including Dynamics 365, Azure and Teams well as Cloud for Healthcare, Exeevo platforms are verticalised for customer and patient experiences, delivered by biopharma, medical devices, biotech and consumer health organisations. About the author.